Obinutuzumab for CTD-Related Interstitial Lung Disease in adults
Official title: 1/2 Efficacy and Safety of Obinutuzumab in Connective Tissue Disease-Related Interstitial Lung Disease
Funded at National Jewish Health · NIH-11451497 · Data updated 2026-11-12
This project tests whether the anti-B cell therapy obinutuzumab can help adults with connective tissue disease–related ILD who are on mycophenolate therapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | National Jewish Health NIH-funded |
| Lab location | 1 site (Denver, United States) |
| Project start | September 4, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $1,000,770 |
| NIH project number | 1UG3HL183035-01A1 |
| Project ID | NIH-11451497 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults 21 years or older with connective tissue disease–related ILD who are on background mycophenolate therapy and meet study criteria.
✕Less likely to help
Patients without CTD-ILD or those not on mycophenolate, or those experiencing contraindications to obinutuzumab, may not benefit.
What this research studies
Adults with connective tissue disease who develop interstitial lung disease and are treated with mycophenolate may be eligible to participate in a two-phase study evaluating obinutuzumab. The first year will prepare the study infrastructure and documents, followed by a Phase II trial to test the drug given intravenously on days 1 and 15 alongside ongoing mycophenolate. The goal is to determine if obinutuzumab can improve lung disease activity and safety in this patient population. This work builds on prior B cell–targeted approaches and seeks high-quality evidence to guide care for CTD-ILD.
Why it matters
Potential benefit: If successful, patients with CTD-ILD may experience improved lung function and quality of life with a targeted B cell therapy added to their current treatment.
How similar studies have gone: Previous studies suggest potential benefit of B cell–targeted therapies in CTD-ILD, but high-quality trial data are lacking and this study aims to provide rigorous evidence.
Where this research is happening
-
National Jewish Health
Denver, United States Active
Researchers
- Principal investigator: Fernandez, Evans R — National Jewish Health
- Study coordinator: Fernandez, Evans R
Related research
Other NIH-funded projects on the same topics.
-
Obinutuzumab for connective tissue disease–related interstitial lung disease in adults
A study will test whether Obinutuzumab, given with standard treatments, can help adults with CTD-ILD breathe better and have fewer disease-related problems.
-
Risk factors and biomarkers for progression of subclinical RA-related lung disease
This study follows people with rheumatoid arthritis to understand who develops lung disease and what biomarkers predict it.
-
Understanding how a cell protein (SLC9A1) drives skin and lung scarring in systemic sclerosis
A five-year NIH grant aims to understand how a specific cell protein called SLC9A1 influences scar-forming cells in systemic sclerosis and related lung disease, with the goal of finding possible therapies.
-
From proteins and genes to new treatments for scar-related lung disease
A large NIH grant is working to map the proteins in the lungs of people with systemic sclerosis to find new targets for drugs that could slow or stop lung fibrosis.
-
Vasculopathy in Systemic Sclerosis and Lung Disease in Adults
A study in adults with systemic sclerosis will look at how blood vessels in the lungs and body relate to the development of lung disease, with the aim of finding new ways to prevent it.
-
Understanding why a rare pediatric lung disease happens and how to treat it
Aims to uncover the molecular causes of pediatric interstitial lung disease and use that knowledge to develop targeted therapies for children affected by this condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.